info@seagull-health.com
SeagullHealth
语言:
search
How well does LYTGOBI(Futibatinib) work?
In Study TAS-120-101 (N=103), LYTGOBI demonstrated an ORR of 42% (95% CI: 32–52%), with 43 partial responses and a median DoR of 9.7 months (95% CI: 7.6–17.1).
Clinical Efficacy in FGFR2-Driven Tumors
Responses were observed in patients with FGFR2 fusions (78%) or rearrangements (22%), with a median time to response of 2.5 months. Efficacy was consistent across prior therapy lines (1–3+), including platinum-based regimens. Accelerated approval hinges on ongoing confirmatory trials to validate survival benefits. No data exist for pediatric or non-FGFR2-altered populations.
Related Columns
Futibatinib(LYTGOBI)
Unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma...
WeChat Scan
Free Inquiry
Free Inquiry
Related articles
共 1 条
- 1
Departments
New Articles
New Drugs
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
Contact Us
- mailbox：info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved